Home » Business News » 2011 » March » March 29, 2011

Ad hoc:Carl Zeiss Meditec AG:Ad hoc:Change to the Management Board

March 29, 2011 - London

Carl Zeiss Meditec AG / /Ad hoc:Change to the Management Board . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Following its Supervisory Board meeting, Carl Zeiss Meditec AG (ISIN: DE0005313704) this evening announces that, after nine years of successful work as a member of the Management Board, Mr. Ulrich Krauss shall end his membership of the Management Board early at the close of business on 12 April 2011, to join the management of Carl Zeiss Vision International GmbH, a subsidiary of Carl Zeiss AG. Mr. Krauss is taking this step at his own request and with the agreement of the Supervisory Board and the Management Board.
With effect from 1 April 2011, Mr. Thomas Simmerer shall be appointed to Carl Zeiss Meditec's Management Board. Mr. Simmerer is responsible within Carl Zeiss Meditec for the strategic business unit Microsurgery and shall succeed Mr. Ulrich Krauss as Chief Sales Officer.
The Supervisory Board would like to thank Mr. Krauss for his dedication and successful work on Carl Zeiss Meditec's Management.


--- End of Message ---

Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany

WKN: 531370;ISIN: DE0005313704;Index:Prime All Share,TECH All Share,TecDAX;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Carl Zeiss Meditec AG via Thomson Reuters ONE



Comment on this story